Open AccessLocoregional Therapies for the Treatment of Uveal Melanoma Hepatic Metastases
Author(s) -
Carin F. Gonsalves,
Robert D. Adamo,
David J. Eschelman
Publication year - 2020
Publication title -
seminars in interventional radiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.35
H-Index - 40
eISSN - 1098-8963
pISSN - 0739-9529
DOI - 10.1055/s-0040-1720948
Subject(s) - medicine , melanoma , percutaneous , ocular melanoma , radiology , disease , metastasis , oncology , cancer , cancer research
Uveal melanoma is the most common primary intraocular malignant tumor in adults. Approximately 50% of patients develop metastatic disease of which greater than 90% of patients develop hepatic metastases. Following the development of liver tumors, overall survival is dismal with hepatic failure being the cause of death in nearly all cases. To prolong survival for patients with metastatic uveal melanoma, controlling the growth of hepatic tumors is essential. This article will discuss imaging surveillance following the diagnosis of primary uveal melanoma; locoregional therapies used to control the growth of hepatic metastases including chemoembolization, immunoembolization, radioembolization, percutaneous hepatic perfusion, and thermal ablation; as well as currently available systemic treatment options for metastatic uveal melanoma.